21 October 2021>: Clinical Research
Integrating Intrinsic Radiosensitivity and Immune Status for Predicting Benefits of Radiotherapy in Head and Neck Squamous Cell Carcinoma
Chuyao Sun 12ADE , Miao Zhang 1BCF , Qiao Qiao 1ADE , Yanli Wang 1C*DOI: 10.12659/MSM.932126
Med Sci Monit 2021; 27:e932126
Table 4 Univariate and multivariate Cox regression analyses of interaction between RSS (as continues variable) and RT in training and validation cohort.
Variables | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
RSI * RT | 0.650 (0.393–1.074) | 0.093 | ||
Immune score * RT | 0.999 (0.999–1.000) | 0.004 | 0.999 (0.999–1.000) | 0.249 |
RSS * RT | 2.873 (1.431–5.769) | 0.003 | 3.367 (1.323–8.565) | 0.011 |
Clinical stage * RT | 0.980 (0.899–1.068) | 0.638 | ||
Neoplasm histologic grade * RT | 0.956 (0.832–1.099) | 0.527 | ||
Lymphovascular invasion * RT | 1.233 (0.920–1.636) | 0.146 | ||
Margin status * RT | 1.401 (1.055–1.861) | 0.020 | 0.982 (0.679–1.420) | 0.923 |
Pathological nodal extra-capsular * RT | 1.720 (1.324–2.234) | 4.83e–05 | 1.953 (1.466–2.603) | 4.8e–06 |
RSI * RT | 0.588 (0.304–1.139) | 0.166 | ||
Immune score * RT | 1.000 (0.999–1.000) | 0.671 | ||
RSS * RT | 3.109 (1.216–7.952) | 0.018 | 3.073 (1.004–9.406) | 0.049 |
Clinical stage * RT | 0.919 (0.829–1.019) | 0.110 | ||
Neoplasm histologic grade * RT | 0.923 (0.775–1.099) | 0.367 | ||
Lymphovascular invasion * RT | 0.936 (0.639–1.371) | 0.735 | ||
Margin status * RT | 0.863 (0.568–1.312) | 0.492 | ||
Pathological nodal extra-capsular * RT | 1.527 (1.104–2.111) | 0.011 | 1.534 (1.110–2.119) | 0.010 |
RT – radiotherapy; RSI – radiosensitivity index; RSS – radiosensitivity signature; HR – hazard ratio; 95% CI – 95% confidence interval. |